A Phase II,Randomized,Cross-over,Double-blind, Placebo- Controlled,Single Center Study of the Effect of Empagliflozin a SGLT-2 Inhibitor,on Endogenous Glucose Production and Plasma Glucagon Levels in Patients With ESRD
Latest Information Update: 24 Oct 2019
At a glance
- Drugs Empagliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- 22 Oct 2019 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.
- 22 Oct 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Jun 2020.
- 25 Oct 2018 New trial record